JP6851149B2 - ピペリジン化合物の製造方法 - Google Patents
ピペリジン化合物の製造方法 Download PDFInfo
- Publication number
- JP6851149B2 JP6851149B2 JP2016127422A JP2016127422A JP6851149B2 JP 6851149 B2 JP6851149 B2 JP 6851149B2 JP 2016127422 A JP2016127422 A JP 2016127422A JP 2016127422 A JP2016127422 A JP 2016127422A JP 6851149 B2 JP6851149 B2 JP 6851149B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- formula
- efinaconazole
- salt
- strong organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 piperidine compound Chemical class 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 claims description 44
- 229960003937 efinaconazole Drugs 0.000 claims description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 150000007530 organic bases Chemical class 0.000 claims description 10
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical group [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 claims description 8
- 229910003002 lithium salt Inorganic materials 0.000 claims description 8
- 159000000002 lithium salts Chemical class 0.000 claims description 8
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 7
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000003880 polar aprotic solvent Substances 0.000 claims description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010992 reflux Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LPKIGDXRQSIQBA-UHFFFAOYSA-N 4-methylidenepiperidine Chemical compound C=C1CCNCC1 LPKIGDXRQSIQBA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- PSQLFRAMDVKEDN-XPCCGILXSA-N C[C@H](C(C[n]1ncnc1)c(c(F)c1)ccc1F)N(CC1)CCC1=C Chemical compound C[C@H](C(C[n]1ncnc1)c(c(F)c1)ccc1F)N(CC1)CCC1=C PSQLFRAMDVKEDN-XPCCGILXSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004707 phenolate Chemical class 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 description 1
- 229910001866 strontium hydroxide Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
本発明は、有機溶媒中、強有機塩基およびリチウム塩の存在下における、式(II)の化合物と式(III)の塩との反応、ならびに、必要に応じて、式(I)のエフィナコナゾールからその塩への変換、もしくは、その逆の変換を含む、式(I)のエフィナコナゾールまたはその塩の製造方法を提供する:
本発明の主題は、有機溶媒中、強有機塩基およびリチウム塩の存在下における、式(II)の化合物と式(III)の塩との反応、ならびに、必要に応じて、式(I)のエフィナコナゾールからその塩への変換、もしくは、エフィナコナゾールの塩からその遊離生成物への変換を含む、式(I)のエフィナコナゾール、またはその塩の製造方法である:
LinY
(式中、nは1または2の整数であってよく、Yは、弱配位性アニオンまたは非配位性アニオンである。)。
アセトニトリル40ml、1,1,3,3−テトラメチルグアニジン6.47g(56.16ミリモル)、4−メチレンピペリジン臭化水素酸塩10.0g(56.16ミリモル)、硝酸リチウム2.58g(37.44ミリモル)、および式(II)の化合物9.41g(37.44ミリモル)を、窒素雰囲気下で、250ml多頚フラスコ中に導入する。反応混合物を還流まで加熱して、30時間後に反応を終了する。次いで、混合物を20〜25℃まで冷却し、水20ml、アセトニトリル20mlおよび飽和NaCl溶液5mlで希釈する。相を分離し、水相を酢酸エチル20mlで抽出し、合わせた有機相を濃縮して、メタノール75ml中に溶解させて30℃に加熱し、水で処理して、残渣を得る。混合物を20℃まで冷却して、これらの条件下で1時間維持し、濾別し、次いで、固体をイソプロパノール45ml中に懸濁する。混合物を70℃まで加熱して、p−トルエンスルホン酸一水和物4.95gにより処理する。混合物を、還流温度で3時間維持し、次いで20℃に冷却して濾別する。得られた固体をイソプロパノールで洗浄し、真空下、50℃で乾燥することにより、エフィナコナゾールのp−トルエンスルホン酸塩11.99gを、収率67%、および210nmにおけるHPLC面積%(A%)として計算した、99%を超えるHPLC純度で得る。
実施例1で得られたエフィナコナゾールのp−トルエンスルホン酸塩10.0g(19.21ミリモル)、メタノール/水=4:1の混合物20ml、および活性炭0.2gを、窒素雰囲気下、50ml多頚フラスコに装填して、50〜55℃で30分間加熱する。次いで、混合物を、パーライトパネルを通して濾過し、溶液を、メカニカルスターラーを備えた100ml多頚フラスコに移して、30%NaOH2.82g(21.13ミリモル)を滴下する。次いで、混合物を30〜35℃まで冷却し、水5mlを滴下すると、それがエフィナコナゾール(I)を誘発する。混合物を攪拌下で約30分間放置して、さらに水30mlを滴下する。次いで、混合物を20〜25℃まで冷却して、これらの条件下で一時間維持し、形成された固体を濾別する。真空下、50℃で乾燥した後、6.50gのエフィナコナゾール(I)を、210nmにおけるHPLC面積%(A%)として計算した、99.5%を超えるHPLC純度、および97%の収率で得る。
機械的ブレード攪拌機、温度計およびバブルコンデンサーを備えた500mlフラスコ中、不活性雰囲気下で、4−メチレンピペリジンのp−トルエンスルホン酸塩(96.5g、358ミリモル)を、アセトニトリル(97ml)に懸濁し、そして、1,1,3,3−テトラメチルグアニジン(44.0g、382ミリモル)をゆっくりと滴下することにより添加する。混合物を0℃まで冷却し、固体を濾過し、アセトニトリル80mlで2回洗浄して、廃棄する。硝酸リチウム(24.7g、358ミリモル)、および(2R、3S)−2−(2,4−ジフルオロフェニル)−3−メチル−2−[(1H−1,2,4−トリアゾリル)メチル]オキシラン(60.0g、239ミリモル)を溶液に添加する。混合物を38時間加熱還流し、20℃まで冷却した後、水(120ml)およびトルエン(120ml)を添加する。水相をトルエン(45ml)でカウンター抽出し、合わせた有機相を減圧下で濃縮する。残渣をメタノール(400ml)中に取り、水(400ml)を添加することにより、固体のエフィナコナゾールを沈殿させる。生成物を10℃まで冷却した後、濾別し、55℃で乾燥することにより、エフィナコナゾール(68.3g、196ミリモル)を、黄色/オレンジ色の固体として、82%の収率で得る。150g(789ミリモル)のp−トルエンスルホン酸(PTSA)一水和物を、3つ口フラスコ中、窒素雰囲気下で、イソプロパノール1250mlに懸濁したエフィナコナゾール250g(718ミリモル)に添加し、混合物を70℃で約3時間加熱する。生成物を室温まで冷却した後、濾別し、イソプロパノール300mlで洗浄し、乾燥することにより、エフィナコナゾール335g(収率:90%)をp−トルエンスルホン酸塩として、210nmにおけるHPLC面積%(A%)として計算した、99%を超えるHPLC純度で得る。
Claims (11)
- 前記強有機塩基が、水性環境下で測定したpKaが11よりも大きい塩基である、請求項1に記載の方法。
- 前記強有機塩基が、アルカリ金属アルコキシド、アルカリ金属水素化物および第3級アミンを含む群より選択される、請求項1に記載の方法。
- 前記強有機塩基が、ジアザビシクロウンデセン(DBU)、2,2,6,6−テトラメチルピペリジンおよび1,1,3,3−テトラメチルグアニジンを含む群より選択される、請求項1に記載の方法。
- 前記強有機塩基が、1,1,3,3−テトラメチルグアニジンである、請求項1に記載の方法。
- 前記強有機酸が、3個のハロゲン原子が置換したC2〜C4カルボン酸;および任意に1個以上のハロゲン原子が置換したスルホン酸を含む群より選択される、請求項1〜5のいずれか一項に記載の方法。
- 前記強無機酸が、ハロゲン化水素酸および硝酸を含む群より選択される、請求項1〜6のいずれか一項に記載の方法。
- 前記強無機酸が臭化水素酸である、請求項7に記載の方法。
- 前記強有機酸または強無機酸が、水性環境下で測定したpKaが1よりも小さい酸である、請求項1〜5のいずれか一項に記載の方法。
- 前記溶媒が、極性非プロトン性溶媒;エーテル;ケトン;非極性非プロトン性溶媒;極性プロトン性溶媒および水、または、前述の溶媒2種または3種の混合物、を含む群より選択される、請求項1〜9のいずれか一項に記載の方法。
- 前記溶媒が、アセトニトリルである、請求項10に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102015000028717 | 2015-06-29 | ||
ITUB20151740 | 2015-06-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017036262A JP2017036262A (ja) | 2017-02-16 |
JP6851149B2 true JP6851149B2 (ja) | 2021-03-31 |
Family
ID=54150620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016127422A Active JP6851149B2 (ja) | 2015-06-29 | 2016-06-28 | ピペリジン化合物の製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9932321B2 (ja) |
EP (1) | EP3112360A1 (ja) |
JP (1) | JP6851149B2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20159795A1 (it) * | 2015-12-30 | 2017-06-30 | Procos Spa | Processo per la sintesi di efinaconazolo |
JP7203612B2 (ja) * | 2017-05-19 | 2023-01-13 | 科研製薬株式会社 | エフィナコナゾールの製造及び精製方法 |
KR102622061B1 (ko) * | 2018-12-29 | 2024-01-08 | 비위트 파마슈티컬 컴퍼니 리미티드 | 에피나코나졸의 제조 방법 |
KR102181155B1 (ko) * | 2019-09-26 | 2020-11-20 | 대봉엘에스 주식회사 | 이온성 액체를 매개로 한 에피나코나졸의 신규 제조방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE161257T1 (de) * | 1993-05-10 | 1998-01-15 | Kaken Pharma Co Ltd | Azolylamin-derivat |
EP2612859B1 (en) * | 2010-08-31 | 2015-09-30 | Kaken Pharmaceutical Co., Ltd. | Method for producing 1-triazole-2-butanol derivative |
EP2746260A1 (en) * | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
-
2016
- 2016-06-22 EP EP16175780.2A patent/EP3112360A1/en not_active Withdrawn
- 2016-06-28 JP JP2016127422A patent/JP6851149B2/ja active Active
- 2016-06-28 US US15/194,773 patent/US9932321B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160376253A1 (en) | 2016-12-29 |
JP2017036262A (ja) | 2017-02-16 |
US9932321B2 (en) | 2018-04-03 |
EP3112360A1 (en) | 2017-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2808230C (en) | Process for producing 1-triazole-2-butanol derivatives | |
JP6851149B2 (ja) | ピペリジン化合物の製造方法 | |
JP2016516696A5 (ja) | ||
EP3395813B1 (en) | Voriconazole intermediate and voriconazole synthesis method | |
US20180118714A1 (en) | Process for the preparation of efinaconazole | |
US10040793B2 (en) | Key intermediates and impurities of the synthesis of Apixaban: Apixaban glycol esters | |
CA2942301A1 (en) | Clomiphene synthesis using a single solvent | |
US10710999B2 (en) | Polymorph of an intermediate for palbociclib synthesis | |
US9108990B2 (en) | Cyclopropyl MIDA boronate | |
US9738607B2 (en) | Scalable process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III | |
KR102622061B1 (ko) | 에피나코나졸의 제조 방법 | |
KR102395842B1 (ko) | 에폭시트리아졸 유도체의 신규 제조방법 | |
KR101974388B1 (ko) | 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법 | |
JP4201268B2 (ja) | イミダゾール誘導体およびその塩の製造方法 | |
EP2456758B1 (en) | A process for preparing trisubstituted phenyl derivatives comprising a (1h-1,2,4-triazol-1-yl)alkyl group | |
JPH0456029B2 (ja) | ||
CN103201243A (zh) | 制备5-[1-(4-氯苯基)-亚甲基]-1-羟基甲基-2,2-二甲基-环戊醇的方法 | |
WO2018202537A1 (en) | Process for the preparation of an azolic derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190612 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200902 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210309 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6851149 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |